Glimepirid Abz (Glimepiride)

Glimepirid Abz is indicated for the oral management of type 2 diabetes mellitus in adults when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve target glycemic levels.

• Improves fasting and post‑prandial blood glucose by enhancing endogenous insulin secretion.
• Can be used as monotherapy or in combination with other oral antidiabetic agents such as metformin.
• May be added to basal insulin regimens to further lower HbA1c when needed.
• Intended for patients with preserved pancreatic beta‑cell function.
• Typically prescribed when lifestyle modification alone does not provide adequate control.

Common and serious adverse reactions have been reported with glimepiride; the frequency and severity vary among individuals.

Common

• Mild hypoglycemia, especially if meals are missed or delayed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as skin rash, pruritus, or angioedema.
• Hematologic abnormalities like leukopenia or thrombocytopenia (rare).

Before initiating Glimepirid Abz, clinicians should evaluate several clinical factors to minimize risk.

• Assess renal and hepatic function; dose adjustment may be required in impairment.
• Verify that the patient has sufficient endogenous insulin production.
• Counsel patients on recognizing and managing hypoglycemia.
• Review concomitant use of other sulfonylureas or insulin to avoid additive effects.
• Use cautiously in the elderly due to increased susceptibility to hypoglycemia.
• Avoid in patients with known hypersensitivity to glimepiride or sulfonylureas.
• Consider pregnancy and lactation status; benefits must outweigh potential risks.

Glimepirid Abz may interact with several drugs that affect blood glucose or sulfonylurea metabolism.

Avoid

• Other sulfonylureas or meglitinides (additive hypoglycemic effect).
• Strong CYP2C9 inhibitors such as fluconazole or amiodarone (increase glimepiride levels).
• High‑dose salicylates (enhance hypoglycemia risk).

Use with caution

• Beta‑blockers (may mask hypoglycemia symptoms).
• Thiazide diuretics (can impair glucose tolerance).
• ACE inhibitors or ARBs (monitor renal function and potassium).
• Antidepressants like SSRIs (potentially alter glycemic control).